Life sciences investing rebounds in 2nd-qtr 2010, rising 52% on prior Quarter, says PricewaterhouseCoopers

5 August 2010

Venture capital funding in the Life Sciences sector, which includes the biotechnology and medical device industries, captured the highest total of VC dollars invested during the second quarter of 2010, according to a new PricewaterhouseCoopers (PwC) report, titled Quarterly Recovery, that includes data from the PwC/NVCA MoneyTree Report, based on from Thomson Reuters.

Life Sciences funding for second-quarter 2010 totalled $2.1 billion in 234 deals, which represents an increase of 52% in dollars and a 36% increase in deals from the prior quarter, reversing the performance seen in the first quarter of 2010 when sector investment dropped 27% in dollars and 15% in deals from fourth-quarter 2009.

For the first half of 2010, Life Sciences investments totalled $3.4 billion, a 26% increase from the first half of 2009. The total number of Life Sciences deals rose 18% to 406 in the first half of 2010 from 345 in the first half of 2009.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >